EU approves Zynquista for adults with type 1 diabetes

29 April 2019

There was good news for French pharma major Sanofi (Euronext: SAN) on Friday, with the European Commission granting marketing authorization for Zynquista(sotagliflozin), developed under a cooperation with US firm Lexicon Pharmaceuticals (Nasdaq: LXRX), at once-daily doses of 200mg and 400mg, for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes (T1D) mellitus and a body mass index >=27kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy.

Just last month, The US Food and Drug Administration issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista, but the companies gave no indication as to what additional data was required, with that news sending Lexicon’s shares plunging as much as 40%.

Blockbuster expectations

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK